Prognostic Significance of the Uncertain Resection in NSCLC
NCT ID: NCT06511661
Last Updated: 2024-07-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
3783 participants
OBSERVATIONAL
2024-07-16
2025-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Factors Determine the Feasibility and Surgical Margin Quality of Sublobar Resection for Non-small Cell Lung Cancer?
NCT07005401
A Real-world Study to Explore Recurrence/Metastases of the NSCLC Patients and the Impact Factors of Patient Survivals
NCT03710616
Postoperative Chronic Operation-related Symptoms After Minimally Invasive Lung Surgery
NCT06016881
Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
NCT06255197
Omitting of Lymphadenectomy is Acceptable for Lung Cancer Smaller Than 6 mm in Solid Size
NCT06516796
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
R0 group
Patients with NSCLC who underwent R0 surgery according to the R stage proposed by IASLC.
Complete lymphadenectomy
At least 3 N1 stations and 3 N2 stations are examined during surgery, including station 7.
R(un) group
Patients with NSCLC who underwent R(un) surgery according to the R stage proposed by IASLC.
Incomplete lymphadenectomy
Less than 3 N1 stations or 3 N2 stations are examined during surgery, or those without station 7 lymph node dissection.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Complete lymphadenectomy
At least 3 N1 stations and 3 N2 stations are examined during surgery, including station 7.
Incomplete lymphadenectomy
Less than 3 N1 stations or 3 N2 stations are examined during surgery, or those without station 7 lymph node dissection.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. With pulmonary resection
Exclusion Criteria
2. R1/R2
3. Positive highest mediastinal lymph nodes
4. Operative death
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sun Yat-sen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mu-Zi Yang
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mu-Zi Yang, M.D.
Role: PRINCIPAL_INVESTIGATOR
Sun Yat-sen University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B2024-401
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.